Cost-effectiveness of individualized nutrition and exercise therapy for rehabilitation following hip fracture [PDF]
, 2016 OBJECTIVE: To undertake a cost-utility analysis of the Individual Nutrition Therapy and Exercise Regime: A Controlled Trial of Injured, Vulnerable Elderly (INTERACTIVE) trial. DESIGN: Cost-utility analysis of a randomized controlled trial.
Cameron, Ian D +8 more
core +2 more sources
Cost Effectiveness and Resource Allocation, 2020 Background Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from
Najmeh Moradi +4 more
doaj +1 more source
Sociodemographic differences in symptom severity and duration among women referred to secondary care for menorrhagia in England and Wales: a cohort study from the National Heavy Menstrual Bleeding Audit. [PDF]
, 2018 OBJECTIVE: To examine symptom severity and duration at time of referral to secondary care for heavy menstrual bleeding (HMB) by socioeconomic deprivation, age and ethnicity DESIGN: Cohort analysis of data from the National HMB Audit linked to Hospital ...
Bansi-Matharu, Loveleen +7 more
core +2 more sources
Quality-Adjusted Life-Years without Constant Proportionality [PDF]
Value in Health, 2018 A quality-adjusted life-year is a common unit of measurement in health valuation. Under its constant proportionality assumption, the value of a quality-adjusted life span is defined as the product of preference weight and life span.To empirically identify an alternative functional relationship between life span and value by relaxing the constant ...
Craig, Benjamin M. +3 more
openaire +3 more sources
Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study. [PDF]
, 2016 BACKGROUND: Potentially inappropriate prescribing (PIP) describes medications where risk generally outweighs benefit for older people. Cross-sectional studies suggest an association between PIP and poorer health outcomes but there is a paucity of ...
Bennett, Kathleen +4 more
core +4 more sources
THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES
Фармакоэкономика, 2017 This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the ...
N. Z. Musina, V. K. Fedyaeva
doaj +1 more source
SAGE Open Medicine, 2023 Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined.
Takenori Ichimura +2 more
doaj +1 more source
BMC Gastroenterology, 2020 Background Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with ...
Maximilian Sieg +3 more
doaj +1 more source
Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen [PDF]
, 2007 Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.Objective: To compare the cost ...
B Dahlof +8 more
core +1 more source
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
PLoS ONE, 2022 AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes +10 more
doaj +2 more sources